Users Discontinuing Anti-Obesity Injections Regain Pounds at a Quadrupled Rate Than Those on Conventional Diets

Fresh analysis suggests that people who come off popular GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise regimens.

Findings released in a leading medical journal points out that while overweight people frequently drop a large proportion of their total mass while using the jabs, the weight returns at an average rate of nearly a kilo each month upon discontinuation.

"Users purchasing these drugs need to be informed of the potential of fast rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.

Such speed of recovery suggests a reversion to starting weight within about one and a half years.

Weighing Treatments

The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with other pills.

Scientists emphasize that individuals who lose weight through lifestyle changes alone generally see a slower weight regain—approximately 100 grams monthly—after stopping.

Explaining the Fast Rebound

Nutrition scientists propose the mode of action of the jabs accounts for the accelerated regain.

GLP-1 drugs imitate a natural hormone called GLP-1, which moderates feelings of fullness.

"Artificially providing GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.

"Stopping of this hormone supplement means hunger is uncontrolled, making excessive eating far more likely."

An Ongoing Issue?

The NHS suggest the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications.

A number of clinicians contend that, considering the significant potential of relapse, the treatment is often life-long.

This perspective is supported by pharmaceutical companies, who say that the results "emphasize the long-term nature of obesity," similar to managing conditions like hypertension.

User Testimonies

People who have come off the jabs explain a intense resurgence of hunger.

"It was like a switch that goes on and you're instantly extremely hungry," described one woman.

This challenge is worsened if users have not established permanent dietary or behavioural modifications during treatment.

Significant Interest

Recent estimates suggest that millions of adults in the UK have tried these injections in the past year, with demand continuing to grow.

• Adoption is greater among women than males.
• The middle-aged age group shows the greatest level of interest.
• Many obtain the medications through private prescriptions rather than public health services.

Finally, clinicians caution that while the jabs are potent tools for weight loss, they are not a permanent solution and long-term success hinges on integrated lifestyle changes.